KYMR Kymera Therapeutics, Inc. - Common Stock
$119,95
Kurs · Aug 18, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$40–$130
89% of range
Analystenbewertung
BUY
30 analysts
Kursziel
$131
+9% upside
P/E (TTM)
-32.5
ROE
-24.4%
Nettogewinnmarge
-794.0%
Über Kymera Therapeutics, Inc. - Common Stock Unternehmensübersicht von Wikipedia
KYMR Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$119.95
Marktkapitalisierung
$9.75B
P/E (TTM)
-32.5
EPS (TTM)
$-3.69
Umsatz (TTM)
$39M
Dividendenrendite
—
ROE
-24.4%
Verschuldungsgrad
—
52W-Spanne
$40 – $130
KYMR Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$39M
2019-12-31
→
2025-12-31
EPS
$-3.69
2020-12-31
→
2025-12-31
Freier Cashflow
$-234M
2020-12-31
→
2025-12-31
Margen
-794.0%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
KYMR
Peer-Median
P/E (TTM)
-32.5
16.0
P/S (TTM) (K/V (TTM))
248.8
32.5
P/B (K/B)
6.2
3.9
Price / FCF (Kurs / FCF)
-41.6
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
KYMR
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-891.1%
—
Net Profit Margin (Nettogewinnmarge)
-794.0%
-93.3%
ROA
-22.9%
-22.2%
ROE
-24.4%
-37.6%
ROIC
-22.1%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
KYMR
Peer-Median
Current Ratio (Liquiditätsgrad)
10.5
5.7
Quick Ratio
4.3
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
KYMR
Peer-Median
Revenue YoY (Umsatz YoY)
-16.7%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
-5.7%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
2.9%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
KYMR
Peer-Median
KYMR Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
30 Analysten
- Starker Kauf 10 33,3%
- Kauf 16 53,3%
- Halten 4 13,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
22 Analysten · 2026-08-16
Median
$133.00
Jetzt
$119.95
Tief
$111.00
Hoch
$155.00
Median-Ziel
$133.00
+10,9%
Mittelwert-Ziel
$130.91
+9,1%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.00%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.62 | $-0.73 | 0.11% |
| 31. März 2026 | $-0.71 | $-0.90 | 0.19% |
| 31. Dezember 2025 | $-0.97 | $-0.81 | -0.16% |
| 30. September 2025 | $-0.94 | $-0.82 | -0.12% |
| 30. Juni 2025 | $-0.95 | $-0.83 | -0.12% |
| 31. März 2025 | $-0.82 | $-0.93 | 0.11% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| IONS | $12.92B | -33.2 | — | — | -68.1% | — |
| SYRE | $2.56B | 10.1 | -62.0% | — | -26.5% | — |
| PCVX | $6.05B | -8.2 | — | — | -26.6% | — |
| IMVT | $5.07B | -9.0 | 229.2% | — | -73.7% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $47M | $79M | $47M | $73M | $34M | $3M | |
| Cost of Revenue | $39M | $47M | $79M | $47M | · | · | · | |
| R&D Expense | $317M | $240M | $189M | $164M | $137M | $62M | $37M | |
| SG&A Expense | $68M | $64M | $55M | $44M | $36M | $18M | $8M | |
| Operating Expenses | $389M | $309M | $244M | $208M | $173M | $80M | $45M | |
| Operating Income | $-349M | $-262M | $-166M | $-161M | $-101M | $-46M | $-42M | |
| Other Non-op | $38M | $38M | $19M | $6M | $313.0K | $711.0K | $959.0K | |
| Pretax Income | $-311M | · | · | · | · | · | · | |
| Income Tax | $0 | · | · | $0 | $0 | $0 | $0 | |
| Net Income | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | $-41M | |
| EPS (Basic) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| EPS (Diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| Shares (Basic) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| Shares (Diluted) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| EBITDA | $-341M | $-254M | $-162M | $-158M | $-98M | $-45M | · |
Bilanz 21
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $357M | $120M | $110M | $68M | $48M | $31M | $76M | |
| Receivables | $0 | $0 | $15M | $0 | · | · | · | |
| Prepaid Expense | $23M | $22M | $12M | $10M | $9M | $5M | $888.0K | |
| Current Assets | $871M | $510M | $405M | $419M | $451M | $302M | $93M | |
| PP&E (Net) | $43M | $50M | $48M | $13M | $12M | $11M | $4M | |
| PP&E (Gross) | $65M | $67M | $59M | $20M | $16M | $13M | $5M | |
| Accum. Depreciation | $22M | $16M | $10M | $7M | $4M | $2M | $1M | |
| Other Non-current Assets | $9M | $2M | $2M | $3M | $2M | $30.0K | $2M | |
| Total Assets | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Accounts Payable | $4M | $6M | $7M | $4M | $4M | $4M | $3M | |
| Accrued Liabilities | $42M | $35M | $34M | $28M | $23M | $10M | $5M | |
| Current Liabilities | $83M | $68M | $86M | $71M | $93M | $111M | $35M | |
| Capital Leases | $67M | $72M | $77M | $12M | $13M | $14M | $17M | |
| Other Non-current Liabilities | · | $0 | $0 | $248.0K | $66.0K | $100.0K | · | |
| Total Liabilities | $163M | $142M | $181M | $113M | $146M | $203M | $82M | |
| Common Stock | $8.0K | $7.0K | $6.0K | $6.0K | $5.0K | $4.0K | · | |
| Retained Earnings | $-1.07B | $-755M | $-531M | $-384M | $-229M | $-129M | $-76M | |
| AOCI | $2M | $-1M | $-552.0K | $-5M | $-660.0K | $-128.0K | $6.0K | |
| Stockholders' Equity | $1.58B | $836M | $395M | $490M | $460M | $284M | $-74M | |
| Liabilities + Equity | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Shares Outstanding | 81,323,532 | 64,890,193 | 55,585,305 | 55,039,380 | 51,536,181 | 44,482,186 | 1,929,516 |
Cashflow 9
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $8M | $7M | $4M | $3M | $2M | $2M | $825.0K | |
| Stock-based Comp | $60M | $55M | $43M | $35M | $25M | $5M | $1M | |
| Other Non-cash | $10M | $-33M | $-3M | $-37M | $-56M | $127M | · | |
| Operating Cash Flow | $-233M | $-195M | $-103M | $-153M | $-129M | $88M | $18M | |
| CapEx | $1M | $13M | $34M | $3M | $2M | $9M | $532.0K | |
| Investing Cash Flow | $-521M | $-404M | $140M | $21M | $-100M | $-423M | $-16M | |
| Financing Cash Flow | $991M | $609M | $4M | $153M | $250M | $289M | $35M | |
| Net Change in Cash | $237M | $10M | $41M | $20M | $21M | $-45M | $36M | |
| Free Cash Flow | $-234M | $-207M | $-137M | $-156M | $-131M | $79M | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | · | |
| Net Margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | · | |
| Pretax Margin | -794.0% | · | · | · | · | · | · | |
| EBITDA Margin | -869.9% | -540.2% | -206.1% | -338.0% | -134.7% | -130.9% | · | |
| ROA | -22.9% | -28.8% | -24.9% | -25.6% | -18.3% | -15.1% | · | |
| ROE | -24.4% | -25.9% | -37.2% | -30.9% | -21.3% | -15.8% | · | |
| ROIC | -22.1% | · | · | · | · | · | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 | 2.7 | · | |
| Quick Ratio | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 | 0.3 | · |
Effizienz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | · | |
| Receivables Turnover | · | 6.3 | 10.5 | · | · | · | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% | · | · | |
| Revenue CAGR 3Y | -5.7% | -13.5% | 32.2% | · | · | · | · | |
| Revenue CAGR 5Y | 2.9% | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $39M | $47M | $79M | $47M | $73M | $34M | · | |
| Net Income TTM | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | · | |
| Market Cap | $6.33B | $2.61B | · | $1.37B | $3.27B | $2.76B | · | |
| P/E | -21.1 | -13.5 | -10.1 | -8.7 | -30.4 | -19.7 | · | |
| P/S | 161.4 | 55.5 | · | 29.3 | 44.9 | 81.0 | · | |
| P/B | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Tangible Book | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Cash Flow | -27.2 | -13.4 | · | -9.0 | -25.4 | 31.3 | · | |
| P / FCF | -27.0 | -12.6 | · | -8.8 | -25.1 | 34.9 | · | |
| Earnings Yield | -4.7% | -7.4% | -9.9% | -11.5% | -3.3% | -5.1% | · |
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | $48M | $5M | $17M | $9M | $16M | $10M | |
| Cost of Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | · | · | · | · | · | · | |
| R&D Expense | $119M | $98M | $84M | $74M | $78M | $80M | $72M | $60M | $59M | $49M | $53M | $48M | $46M | $42M | $43M | $44M | |
| SG&A Expense | $21M | $20M | $17M | $17M | $18M | $16M | $16M | $15M | $17M | $14M | $14M | $14M | $14M | $13M | $12M | $11M | |
| Operating Expenses | $141M | $119M | $101M | $95M | $96M | $97M | $88M | $76M | $77M | $68M | $67M | $62M | $60M | $55M | $55M | $54M | |
| Operating Income | $-76M | $-84M | $-98M | $-93M | $-85M | $-74M | $-81M | $-72M | $-51M | $-58M | $-19M | $-58M | $-43M | $-45M | $-39M | $-45M | |
| Other Non-op | $14M | $15M | $11M | $10M | $8M | $9M | $10M | $10M | $9M | $9M | $5M | $5M | $5M | $4M | $4M | $2M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $100.0K | $100.0K | $0 | · | $0 | |
| Net Income | $-61M | $-69M | $-87M | $-82M | $-77M | $-66M | $-71M | $-62M | $-42M | $-49M | $-14M | $-53M | $-39M | $-41M | $-35M | $-43M | |
| EPS (Basic) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| EPS (Diluted) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| Shares (Basic) | 98,177,158 | 97,534,269 | -163,405,637 | 87,300,286 | 80,449,405 | 80,146,531 | -144,911,702 | 76,125,975 | 73,059,398 | 70,770,320 | -116,570,361 | 58,421,859 | 58,326,963 | 58,187,038 | -104,025,850 | 54,535,514 | |
| Shares (Diluted) | 98,177,158 | 97,534,269 | -163,405,637 | 87,300,286 | 80,449,405 | 80,146,531 | -144,911,702 | 76,125,975 | 73,059,398 | 70,770,320 | -116,570,361 | 58,421,859 | 58,326,963 | 58,187,038 | -104,025,850 | 54,535,514 | |
| EBITDA | $-76M | $-82M | · | $-93M | $-85M | $-72M | · | $-72M | $-51M | $-56M | · | $-58M | $-43M | $-44M | · | $-45M |
Bilanz 21
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $124M | $144M | $357M | $113M | $336M | $90M | $120M | $111M | $68M | $94M | $110M | $81M | $52M | $50M | $68M | $156M | |
| Receivables | $20M | · | · | · | $40M | · | · | $0 | $0 | $0 | · | · | · | · | · | · | |
| Prepaid Expense | $26M | $27M | $23M | $23M | $23M | $18M | $22M | $17M | $14M | $15M | · | $14M | $14M | $11M | · | $9M | |
| Current Assets | $737M | $677M | $871M | $528M | $728M | $501M | $510M | $569M | $525M | $537M | · | $376M | $385M | $412M | · | $494M | |
| PP&E (Net) | $40M | $42M | $43M | $45M | $49M | $49M | $50M | $51M | $52M | $49M | · | $36M | $27M | $17M | · | $13M | |
| PP&E (Gross) | $66M | $66M | $65M | $67M | $69M | $67M | $67M | $65M | $64M | $60M | · | $46M | $36M | $25M | · | $19M | |
| Accum. Depreciation | $26M | $24M | $22M | $22M | $20M | $18M | $16M | $14M | $12M | $11M | · | $10M | $9M | $8M | · | $6M | |
| Other Non-current Assets | $7M | $8M | $9M | $7M | $5M | $3M | $2M | $0 | $2M | $2M | · | $3M | $3M | $3M | · | $3M | |
| Total Assets | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Accounts Payable | $9M | $13M | $4M | $6M | $6M | $10M | $6M | $6M | $7M | $7M | · | $5M | $4M | $6M | · | $6M | |
| Accrued Liabilities | $48M | $35M | $42M | $29M | $28M | $23M | $35M | $27M | $24M | $16M | · | $26M | $22M | $19M | · | $25M | |
| Current Liabilities | $71M | $63M | $83M | $72M | $88M | $59M | $68M | $67M | $62M | $56M | · | $63M | $55M | $62M | · | $91M | |
| Capital Leases | $64M | $66M | $67M | $68M | $70M | $71M | $72M | $74M | $75M | $76M | · | $77M | $71M | $64M | · | $12M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | $8.0K | $230.0K | $237.0K | · | $256.0K | |
| Total Liabilities | $136M | $129M | $163M | $156M | $160M | $132M | $142M | $142M | $141M | $157M | · | $157M | $147M | $152M | · | $126M | |
| Common Stock | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $-1.20B | $-1.14B | $-1.07B | $-979M | $-897M | $-820M | $-755M | $-684M | $-621M | $-579M | · | $-516M | $-464M | $-425M | · | $-349M | |
| AOCI | $-7M | $-4M | $2M | $2M | $279.0K | $-58.0K | $-1M | $2M | $-2M | $-2M | · | $-2M | $-4M | $-3M | · | $-6M | |
| Stockholders' Equity | $1.51B | $1.54B | $1.58B | $946M | $971M | $786M | $836M | $893M | $685M | $711M | $395M | $396M | $435M | $462M | $490M | $513M | |
| Liabilities + Equity | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Shares Outstanding | 82,788,253 | 82,182,101 | 81,323,532 | 71,741,174 | 70,557,442 | 65,112,714 | 64,890,193 | 64,748,226 | 61,572,383 | 61,353,146 | · | 55,450,239 | 55,390,259 | 55,276,226 | · | 54,751,429 |
Cashflow 9
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $891.0K | $895.0K | $900.0K | $879.0K | $818.0K | $767.0K | |
| Stock-based Comp | $19M | $16M | $14M | $16M | $15M | $14M | $14M | $15M | $14M | $12M | $11M | $12M | $11M | $9M | $9M | $9M | |
| Other Non-cash | · | $-38M | · | · | · | $-30M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-54M | $-89M | $-67M | $-27M | $-60M | $-79M | $-62M | $-50M | $-43M | $-40M | $8M | $-32M | $-35M | $-44M | $-40M | $-34M | |
| CapEx | $473.0K | $434.0K | $106.0K | $181.0K | $695.0K | $467.0K | $936.0K | $-189.0K | $5M | $7M | $12M | $8M | $11M | $4M | $373.0K | $1M | |
| Investing Cash Flow | $20M | $-143M | $-394M | $-235M | $60M | $49M | $69M | $-158M | $16M | $-331M | $19M | $61M | $36M | $25M | $-50M | $-37M | |
| Financing Cash Flow | $14M | $19M | $705M | $40M | $246M | $258.0K | $3M | $251M | $1M | $354M | $2M | $-206.0K | $1M | $1M | $2M | $150M | |
| Net Change in Cash | $-20M | $-213M | $244M | $-223M | $246M | $-30M | $10M | $43M | $-26M | $-16M | $29M | $29M | $2M | $-18M | $-87M | $79M | |
| Free Cash Flow | · | $-89M | · | · | · | $-80M | · | · | · | $-47M | · | · | · | $-48M | · | · |
Rentabilität 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -116.3% | -244.9% | · | -3347.4% | -736.8% | -336.8% | · | -1927.9% | -198.5% | -562.2% | · | -1216.4% | -262.7% | -478.8% | · | -469.9% | |
| Net Margin | -94.2% | -201.5% | · | -2973.0% | -667.6% | -296.8% | · | -1670.3% | -164.0% | -472.0% | · | -1118.2% | -235.0% | -432.4% | · | -450.2% | |
| EBITDA Margin | -116.3% | -239.0% | · | -3347.4% | -736.8% | -327.5% | · | -1927.9% | -198.5% | -548.0% | · | -1216.4% | -262.7% | -469.5% | · | -469.9% | |
| ROA | -4.4% | -5.3% | · | -7.7% | -7.8% | -7.3% | · | -7.9% | -6.0% | -6.6% | · | -8.9% | -7.0% | -7.0% | · | -6.7% | |
| ROE | -4.9% | -5.9% | · | -8.9% | -9.2% | -8.8% | · | -9.7% | -7.5% | -8.3% | · | -11.6% | -9.3% | -9.2% | · | -8.6% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.3 | 10.8 | · | 7.4 | 8.3 | 8.5 | · | 8.5 | 8.5 | 9.6 | · | 5.9 | 7.1 | 6.6 | · | 5.4 | |
| Quick Ratio | 2.0 | 2.3 | · | 1.6 | 4.3 | 1.5 | · | 1.7 | 1.1 | 1.7 | · | 1.3 | 1.0 | 0.8 | · | 1.7 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 2.2 | · | · | · | 0.6 | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $114M | $71M | · | $40M | $63M | $62M | · | $44M | $57M | $41M | · | $40M | $47M | $40M | · | $51M | |
| Net Income TTM | $-289M | $-294M | · | $-287M | $-247M | $-219M | · | $-206M | $-182M | $-181M | · | $-176M | $-163M | $-161M | · | $-149M | |
| Market Cap | $9.49B | $6.84B | · | $4.06B | $3.08B | $1.78B | · | $3.06B | $1.84B | $2.47B | · | $771M | $1.27B | $1.64B | · | $1.19B | |
| P/E | -35.6 | -24.4 | · | -16.0 | -13.8 | -9.4 | · | -15.8 | -10.5 | -13.6 | · | -4.5 | -7.8 | -9.9 | · | -7.7 | |
| P/S | 83.6 | 96.8 | · | 101.3 | 48.9 | 28.8 | · | 69.0 | 32.1 | 60.2 | · | 19.1 | 27.1 | 40.8 | · | 23.4 | |
| P/B | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Tangible Book | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Cash Flow | · | -77.0 | · | · | · | -22.5 | · | · | · | -62.3 | · | · | · | -37.3 | · | · | |
| P / FCF | · | -76.7 | · | · | · | -22.4 | · | · | · | -52.5 | · | · | · | -34.1 | · | · | |
| Earnings Yield | -2.8% | -4.1% | · | -6.2% | -7.3% | -10.6% | · | -6.3% | -9.5% | -7.4% | · | -22.0% | -12.8% | -10.1% | · | -13.1% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $39M | $47M | $79M | $47M | $73M |
| Betriebsgewinnmarge % | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% |
| Nettoergebnis | $-311M | $-224M | $-147M | $-155M | $-100M |
| Verwässerte EPS | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 |
| Quick Ratio | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-234M | $-207M | $-137M | $-156M | $-131M |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 305 Einreicher · $8.0B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 58 (+19 vs. Vorquartal) | 22 (-14 vs. Vorquartal) | 94 (+1 vs. Vorquartal) | 78 (+5 vs. Vorquartal) | +11.8M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $992.725.940 | 8.657.242 | 12,48% | Aktien |
| FMR LLC | $985.896.654 | 8.597.686 | 12,40% | Aktien |
| Avoro Capital Advisors LLC | $857.129.238 | 7.474.747 | 10,78% | Aktien |
| BVF INC/IL | $444.008.203 | 3.872.052 | 5,58% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $376.085.378 | 3.279.719 | 4,73% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $343.114.771 | 2.992.193 | 4,31% | Aktien |
| Siren, L.L.C. | $336.651.626 | 2.935.830 | 4,23% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $336.255.785 | 2.932.378 | 4,23% | Aktien |
| Atlas Venture Life Science Advisors, LLC | $326.527.526 | 2.847.541 | 4,11% | Aktien |
| STATE STREET CORP | $313.877.705 | 2.737.226 | 3,95% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $181.558.708 | 1.582.987 | 2,28% | Aktien |
| Capital Research Global Investors | $159.262.984 | 1.388.881 | 2,00% | Aktien |
| Driehaus Capital Management LLC | $105.408.448 | 919.233 | 1,33% | Aktien |
| GOLDMAN SACHS GROUP INC | $101.597.391 | 885.998 | 1,28% | Aktien |
| Merck & Co., Inc. | $88.544.161 | 772.165 | 1,11% | Aktien |
| NORGES BANK | $86.833.399 | 757.246 | 1,09% | Aktien |
| FEDERATED HERMES, INC. | $85.933.469 | 749.398 | 1,08% | Aktien |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $84.955.104 | 740.866 | 1,07% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $81.750.884 | 981.521 | 1,03% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $77.152.155 | 672.819 | 0,97% | Aktien |
| Holocene Advisors, LP | $72.996.514 | 636.579 | 0,92% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $60.744.024 | 529.729 | 0,76% | Aktien |
| EVENTIDE ASSET MANAGEMENT, LLC | $57.811.287 | 504.210 | 0,73% | Aktien |
| JENNISON ASSOCIATES LLC | $57.676.487 | 502.978 | 0,73% | Aktien |
| Woodline Partners LP | $57.434.534 | 500.868 | 0,72% | Aktien |
| Rock Springs Capital Management LP | $51.963.399 | 453.156 | 0,65% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $51.570.654 | 449.731 | 0,65% | Aktien |
| Boxer Capital Management, LLC | $49.204.897 | 429.100 | 0,62% | Aktien |
| Pictet Asset Management Holding SA | $44.984.008 | 395.540 | 0,57% | Aktien |
| BRAIDWELL LP | $43.363.951 | 378.163 | 0,55% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $43.100.784 | 375.868 | 0,54% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $42.585.457 | 371.374 | 0,54% | Aktien |
| Clearbridge Investments, LLC | $39.815.871 | 347.221 | 0,50% | Aktien |
| Octagon Capital Advisors LP | $35.547.700 | 310.000 | 0,45% | Aktien |
| Nextech Invest Ltd. | $31.981.004 | 278.896 | 0,40% | Aktien |
| Alyeska Investment Group, L.P. | $31.701.095 | 276.455 | 0,40% | Aktien |
| TD Asset Management Inc | $31.293.443 | 272.900 | 0,39% | Aktien |
| TWO SIGMA ADVISERS, LP | $29.085.378 | 373.800 | 0,37% | Aktien |
| Commodore Capital LP | $28.667.500 | 250.000 | 0,36% | Aktien |
| RTW INVESTMENTS, LP | $27.520.800 | 240.000 | 0,35% | Aktien |
| GILDER GAGNON HOWE & CO LLC | $26.265.508 | 229.053 | 0,33% | Aktien |
| Polar Capital Holdings Plc | $23.363.668 | 203.747 | 0,29% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22.934.000 | 200.000 | 0,29% | Aktien |
| Candriam S.C.A. | $22.096.270 | 192.880 | 0,28% | Aktien |
| BANK OF AMERICA CORP /DE/ | $21.627.335 | 188.605 | 0,27% | Aktien |
| Eagle Health Investments LP | $19.052.191 | 166.148 | 0,24% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $17.189.950 | 149.908 | 0,22% | Aktien |
| DIADEMA PARTNERS LP | $17.166.099 | 149.700 | 0,22% | Kaufoption |
| Foresite Capital Management VI LLC | $16.779.890 | 146.332 | 0,21% | Aktien |
| WCM INVESTMENT MANAGEMENT, LLC | $16.595.869 | 151.810 | 0,21% | Aktien |
| JANE STREET GROUP, LLC | $15.732.724 | 137.200 | 0,20% | Kaufoption |
| Deer Management Co. LLC | $14.436.380 | 125.895 | 0,18% | Aktien |
| TimesSquare Capital Management, LLC | $14.063.183 | 168.846 | 0,18% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $13.794.801 | 120.300 | 0,17% | Kaufoption |
| Caption Management, LLC | $13.760.400 | 120.000 | 0,17% | Verkaufsoption |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13.703.409 | 119.503 | 0,17% | Aktien |
| BOONE CAPITAL MANAGEMENT LLC | $12.977.548 | 113.173 | 0,16% | Aktien |
| ARMISTICE CAPITAL, LLC | $12.186.210 | 106.272 | 0,15% | Aktien |
| First Turn Management, LLC | $11.757.459 | 102.533 | 0,15% | Aktien |
| Ensign Peak Advisors, Inc | $11.198.672 | 97.660 | 0,14% | Aktien |
| Squarepoint Ops LLC | $11.144.663 | 97.189 | 0,14% | Aktien |
| Swiss National Bank | $10.331.767 | 90.100 | 0,13% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10.262.276 | 89.494 | 0,13% | Aktien |
| Bank of New York Mellon Corp | $9.823.664 | 85.669 | 0,12% | Aktien |
| RHUMBLINE ADVISERS | $9.252.017 | 80.684 | 0,12% | Aktien |
| JPMORGAN CHASE & CO | $9.149.756 | 81.205 | 0,12% | Aktien |
| Burkehill Global Management, LP | $8.600.250 | 75.000 | 0,11% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $8.524.567 | 74.340 | 0,11% | Aktien |
| CITIGROUP INC | $8.504.959 | 74.169 | 0,11% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8.462.646 | 73.800 | 0,11% | Verkaufsoption |
| CITADEL ADVISORS LLC | $8.328.253 | 72.628 | 0,10% | Aktien |
| FIFTH THIRD BANCORP | $7.529.104 | 65.659 | 0,09% | Aktien |
| BlackRock, Inc. | $7.486.231 | 65.285 | 0,09% | Aktien |
| Yiheng Capital Management, L.P. | $7.274.665 | 63.440 | 0,09% | Aktien |
| XTX Topco Ltd | $7.052.320 | 61.501 | 0,09% | Aktien |
| FIRST TRUST ADVISORS LP | $7.037.068 | 61.368 | 0,09% | Aktien |
| Atika Capital Management LLC | $6.957.488 | 60.674 | 0,09% | Aktien |
| Nicholas Investment Partners, LP | $6.257.427 | 54.569 | 0,08% | Aktien |
| Ikarian Capital, LLC | $5.779.368 | 50.400 | 0,07% | Verkaufsoption |
| Patient Square Capital LP | $5.446.825 | 47.500 | 0,07% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $5.250.281 | 45.786 | 0,07% | Aktien |
| PEREGRINE CAPITAL MANAGEMENT LLC | $5.237.094 | 45.671 | 0,07% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4.687.728 | 56.282 | 0,06% | Aktien |
| UBS Group AG | $4.678.880 | 40.803 | 0,06% | Aktien |
| AXA Investment Managers S.A. | $4.558.224 | 80.534 | 0,06% | Aktien |
| VOYA INVESTMENT MANAGEMENT LLC | $4.451.260 | 38.818 | 0,06% | Aktien |
| MARSHALL WACE, LLP | $4.273.177 | 37.265 | 0,05% | Aktien |
| STATE OF WISCONSIN INVESTMENT BOARD | $4.223.640 | 36.833 | 0,05% | Aktien |
| MetLife Investment Management, LLC | $4.184.767 | 36.494 | 0,05% | Aktien |
| Rafferty Asset Management, LLC | $4.046.360 | 35.287 | 0,05% | Aktien |
| Odyssean, LLC | $3.954.395 | 34.485 | 0,05% | Aktien |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $3.851.880 | 33.591 | 0,05% | Aktien |
| CITADEL ADVISORS LLC | $3.841.445 | 33.500 | 0,05% | Verkaufsoption |
| Aquilo Capital Management, LLC | $3.791.320 | 138.521 | 0,05% | Aktien |
| Nan Fung Group Holdings Ltd | $3.540.436 | 30.875 | 0,04% | Aktien |
| Moody Aldrich Partners LLC | $3.440.788 | 30.006 | 0,04% | Aktien |
| SEVEN GRAND MANAGERS, LLC | $3.440.100 | 30.000 | 0,04% | Aktien |
| 683 Capital Management, LLC | $3.440.100 | 30.000 | 0,04% | Verkaufsoption |
| CITADEL ADVISORS LLC | $3.428.633 | 29.900 | 0,04% | Kaufoption |
| NEW YORK STATE COMMON RETIREMENT FUND | $3.300.203 | 28.780 | 0,04% | Aktien |
Unternehmensinsider 24 Insider · 10 Führungskräfte · 13 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Nello Mainolfi | Chief Executive Officer | 7. Juli 2026 M | 666.568 | 0 | 21 | $-34.875.625 |
| Bruce N. Jacobs | Chief Financial Officer | 30. Juni 2026 M | 244.883 | 0 | 16 | $-13.917.105 |
| Jeremy G Chadwick | Chief Operating Officer | 27. Mai 2026 S | 44.018 | 0 | 29 | $-15.599.618 |
| Terence Rooney | Chief Medical Officer | 27. Juli 2026 A | 38.000 | 0 | 0 | $0 |
| Noah Goodman | Chief Business Officer | 1. Juli 2026 S | 47.179 | 0 | 9 | $-2.223.845 |
| Jared Gollob | Chief Medical Officer | 2. März 2026 A | 117.134 | 0 | 18 | $-9.134.491 |
| Brian Adams | Chief Legal Officer | 2. März 2026 A | 56.625 | 0 | 0 | $0 |
| Ellen Chiniara | Chief Legal Officer | 3. März 2025 A | 80.085 | 0 | 0 | $0 |
| Elaine Caughey | Chief Business Officer | 1. März 2023 A | 18.986 | 0 | 0 | $0 |
| Richard Chesworth | Chief Scientific Officer | 27. August 2021 M | 0 | 0 | 0 | $0 |
| Bruce Booth | Direktor | 29. Juni 2026 S | 462.856 | 0 | 137 | $-195.559.433 |
| Hrustanovic Gorjan | Direktor | 24. Juni 2026 A | — | 0 | 0 | $0 |
| Elena Ridloff | Direktor | 24. Juni 2026 A | 0 | 0 | 4 | $-1.285.644 |
| Pamela Esposito | Direktor | 24. Juni 2026 A | 1.000 | 0 | 12 | $-3.054.174 |
| Jeffrey W. Albers | Direktor | 24. Juni 2026 A | 0 | 0 | 3 | $-744.757 |
| Victor Sandor | Direktor | 24. Juni 2026 A | — | 0 | 0 | $0 |
| John Maraganore | Direktor | 24. Juni 2026 A | — | 0 | 0 | $0 |
| Leigh Morgan | Direktor | 18. Juni 2024 A | — | 0 | 0 | $0 |
| Joanna Horobin | Direktor | 7. Juni 2024 M | 0 | 0 | 0 | $0 |
| Donald William Nicholson | Direktor | 15. Juni 2022 A | — | 0 | 0 | $0 |
| Steven Edward Hall | Direktor | 25. August 2020 C | 2.192.249 | 0 | 0 | $0 |
| Andrew Hedin | Direktor | 20. August 2020 A | — | 0 | 0 | $0 |
| Atlas Venture Fund X, L.P. | 10%-Eigentümer | 18. Mai 2021 J | 5.763.012 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10%-Eigentümer | 25. August 2020 C | 959.211 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, LAMPERT MARK N, Hrustanovic Gorjan ×2 Einreichungen | 26. Juni 2026 | 6,30% | Änderung | — | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×4 Einreichungen | 11. Dezember 2025 | 10,90% | Änderung | — | SEC |
| BIOTECHNOLOGY VALUE FUND, L.P., BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II, L.P., BVF II GP LLC, BIOTECHNOLOGY VALUE TRADING FUND OS, L.P., BVF PARTNERS OS LTD., BVF GP HOLDINGS LLC, BVF PARTNERS L.P., BVF INC., MARK N. LAMPERT, GORJAN HRUSTANOVIC ×5 Einreichungen | 9. Januar 2024 | — | Erste Einreichung | — | SEC |
| Vertex Pharmaceuticals Incorporated ×2 Einreichungen | 5. Juni 2023 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 64 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 4,23% | 84.154 NS | 31. Mai 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 1,99% | 10.000 NS | 31. Mai 2026 | N-PORT |
| HAPS · Harbor ETF Trust | 1,76% | 34.157 NS | 30. April 2026 | N-PORT |
| GURU · Global X Funds | 1,04% | 7.506 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 59.553 NS | 30. April 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,67% | 3.077 NS | 30. April 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 4.477 SH | 8. August 2026 | Täglich |
| IBB · iShares Trust | 0,58% | 522.187 SH | 8. August 2026 | Täglich |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,50% | 3.204 NS | 31. Mai 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,39% | 24.697 NS | 30. April 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,35% | 55.351 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,34% | 469.031 SH | 8. August 2026 | Täglich |
| BIB · ProShares Trust | 0,33% | 3.017 NS | 31. Mai 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,33% | 1.305 NS | 31. Mai 2026 | N-PORT |
| ESSC · Strategy Shares | 0,31% | 979 NS | 30. April 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 20.749 NS | 30. April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,22% | 360.394 SH | 8. August 2026 | Täglich |
| VBK · VANGUARD INDEX FUNDS | 0,21% | 871.540 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,21% | 1.586.740 SH | 8. August 2026 | Täglich |
| BKSE · BNY Mellon ETF Trust | 0,19% | 1.938 NS | 30. April 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,19% | 32.324 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,14% | 24.820 NS | 30. April 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,13% | 21.796 NS | 30. April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,12% | 2.699 NS | 31. Mai 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 6.792 NS | 30. April 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,11% | 294.706 NS | 31. Mai 2026 | N-PORT |
| ISCV · iShares Trust | 0,09% | 5.956 SH | 8. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,09% | 1.509.269 SH | 8. August 2026 | Täglich |
| ISCG · iShares Trust | 0,09% | 8.334 SH | 8. August 2026 | Täglich |
| ISCB · iShares Trust | 0,09% | 2.398 SH | 8. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,08% | 22.424 SH | 8. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,08% | 143.695 NS | 30. April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 726.357 SH | 8. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,08% | 9.461 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,08% | 134.854 SH | 8. August 2026 | Täglich |
| ESML · iShares Trust | 0,08% | 21.257 SH | 8. August 2026 | Täglich |
| IWN · iShares Trust | 0,07% | 101.814 SH | 8. August 2026 | Täglich |
| UWM · ProShares Trust | 0,07% | 2.111 NS | 31. Mai 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 21.910 NS | 30. April 2026 | N-PORT |
| URTY · ProShares Trust | 0,05% | 2.136 NS | 31. Mai 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,05% | 61 NS | 31. Mai 2026 | N-PORT |
| WSML · iShares Trust | 0,05% | 2.882 SH | 8. August 2026 | Täglich |
| GSSC · Goldman Sachs ETF Trust | 0,04% | 5.327 NS | 31. Mai 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,03% | 1.604 NS | 31. Mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 2.239 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 54 NS | 31. Mai 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 93.115 NS | 30. April 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 19.514 NS | 31. Mai 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 675 NS | 30. April 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 2.916 NS | 30. April 2026 | N-PORT |